Inovio Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Inovio Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Inovio Pharmaceuticals Inc Strategy Report
- Understand Inovio Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
Headquarters
United States of America
Address
Suite 110, 660 W. Germantown Pike, Plymouth Meeting, Pennsylvania, 19462
Website
www.inovio.com
Telephone
267 440 4200
No of Employees
184
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INO (NASD)
Revenue (2022)
$10.3M
478.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
7.9%
(2022 vs 2021)
Market Cap*
$103.7M
Net Profit Margin (2022)
XYZ
84.1%
(2022 vs 2021)
* As of and is in US$
Inovio Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline products: | - |
| COVID-19: | dMAb |
| INO-4800 | SynCon |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In September, the company announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis. |
| 2023 | Regulatory Approval | In May, the company announced that the European Commission (EC) granted orphan drug designation for INO-3107. |
| 2021 | Regulatory Approval | In November, the company received approval from the Drug Controller General of India for Phase III trial of the Covid-19 vaccine, INO-4800, in India. |
Competitor Comparison
| Key Parameters | Inovio Pharmaceuticals Inc | Pfizer Inc | Merck & Co Inc | Sanofi | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | France | United Kingdom |
| City | Plymouth Meeting | New York | Kenilworth | Paris | Brentford |
| State/Province | Pennsylvania | New York | New Jersey | Ile-de-France | England |
| No. of Employees | 184 | 83,000 | 69,000 | 91,573 | 69,400 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Simon X. Benito | Chairman | Executive Board | 2019 | 78 |
| Jacqueline E. Shea, Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2022 | - |
| Peter D. Kies | Chief Financial Officer | Senior Management | 2002 | 59 |
| Michael Sumner | Chief Medical Officer | Senior Management | 2022 | - |
| Laurent Humeau, Ph.D. | Chief Scientific Officer | Senior Management | 2019 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward